Home >> Research Area >>Others>>Others>> 4E1RCat

4E1RCat

Dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction CAS# 328998-25-0

4E1RCat

Catalog No. BCC5338----Order now to get a substantial discount!

Product Name & Size Price Stock
4E1RCat: 5mg $81 In Stock
4E1RCat: 10mg Please Inquire In Stock
4E1RCat: 20mg Please Inquire Please Inquire
4E1RCat: 50mg Please Inquire Please Inquire
4E1RCat: 100mg Please Inquire Please Inquire
4E1RCat: 200mg Please Inquire Please Inquire
4E1RCat: 500mg Please Inquire Please Inquire
4E1RCat: 1000mg Please Inquire Please Inquire
Related Products
  • Cercosporamide

    Catalog No.:BCC2438
    CAS No.:131436-22-1
  • 4EGI-1

    Catalog No.:BCC5337
    CAS No.:315706-13-9
  • KC7F2

    Catalog No.:BCC2434
    CAS No.:927822-86-4

Quality Control of 4E1RCat

Number of papers citing our products

Chemical structure

4E1RCat

3D structure

Chemical Properties of 4E1RCat

Cas No. 328998-25-0 SDF Download SDF
PubChem ID 16195554 Appearance Powder
Formula C28H18N2O6 M.Wt 478.45
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 5.4 mg/mL (11.29 mM; Need warming)
Chemical Name 4-[(3E)-3-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-2-oxo-5-phenylpyrrol-1-yl]benzoic acid
SMILES C1=CC=C(C=C1)C2=CC(=CC3=CC=C(O3)C4=CC=C(C=C4)[N+](=O)[O-])C(=O)N2C5=CC=C(C=C5)C(=O)O
Standard InChIKey BBQRBOIMSKMFFO-LTGZKZEYSA-N
Standard InChI InChI=1S/C28H18N2O6/c31-27-21(16-24-14-15-26(36-24)19-6-12-23(13-7-19)30(34)35)17-25(18-4-2-1-3-5-18)29(27)22-10-8-20(9-11-22)28(32)33/h1-17H,(H,32,33)/b21-16+
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of 4E1RCat

DescriptionInhibitor of protein translation; blocks eIF4E:eIF4G and eIF4E:4E-BP1 interaction. Prevents assembly of the eIF4F complex and inhibits cap-dependent translation (IC50 ~4 μM). Exhibits chemosensitizing properties.

4E1RCat Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

4E1RCat Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 4E1RCat

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.0901 mL 10.4504 mL 20.9008 mL 41.8017 mL 52.2521 mL
5 mM 0.418 mL 2.0901 mL 4.1802 mL 8.3603 mL 10.4504 mL
10 mM 0.209 mL 1.045 mL 2.0901 mL 4.1802 mL 5.2252 mL
50 mM 0.0418 mL 0.209 mL 0.418 mL 0.836 mL 1.045 mL
100 mM 0.0209 mL 0.1045 mL 0.209 mL 0.418 mL 0.5225 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on 4E1RCat

4E1RCat is a dual inhibitor of eIF4E:4E-BP1 and eIF4E:eIF4G interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM.
The complexity of eIF4A, eIF4E and eIF4G together forms the eIF4F, the eukaryotic initiation factor, which stimulates the loading of ribosomes onto mRNA templates in protein synthesis. The inhibition of this cap-dependent translation is associated with cancer initiation and progression [1].
4E1RCat prevents assembly of the eIF4F complex and inhibits cap-dependent translation [1]. 4E1RCat significantly inhibited 5′-cap-mediated mCherry synthesis while had little effect on the IRES-mediated DIAPH1-HA synthesis, which confirmed the specific inhibitory effect of 4E1RCat on 5′-cap-mediated translation [2].
References:
[1]. Cencic R, Hall DR, Robert F, et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci, 2011, 108(3): 1046-1051.
[2]. Liao G, Liu G. Immediate translation of Formin DIAPH1 mRNA after its exiting the nucleus is required for its perinuclear localization in fibroblasts. PLoS One, 2013, 8(6): e68190.

Featured Products
New Products
 

References on 4E1RCat

Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Augments mRNA Translation.[Pubmed:28515298]

J Virol. 2017 Jul 12;91(15). pii: JVI.00636-17.

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne Nairovirus of the Bunyaviridae family, causing severe illness with high mortality rates in humans. Here, we demonstrate that CCHFV nucleocapsid protein (CCHFV-NP) augments mRNA translation. CCHFV-NP binds to the viral mRNA 5' untranslated region (UTR) with high affinity. It facilitates the translation of reporter mRNA both in vivo and in vitro with the assistance of the viral mRNA 5' UTR. CCHFV-NP equally favors the translation of both capped and uncapped mRNAs, demonstrating the independence of this translation strategy on the 5' cap. Unlike the canonical host translation machinery, inhibition of eIF4F complex, an amalgam of three initiation factors, eIF4A, eIF4G, and eIF4E, by the chemical inhibitor 4E1RCat did not impact the CCHFV-NP-mediated translation mechanism. However, the proteolytic degradation of eIF4G alone by the human rhinovirus 2A protease abrogated this translation strategy. Our results demonstrate that eIF4F complex formation is not required but eIF4G plays a critical role in this translation mechanism. Our results suggest that CCHFV has adopted a unique translation mechanism to facilitate the translation of viral mRNAs in the host cell cytoplasm where cellular transcripts are competing for the same translation apparatus.IMPORTANCE Crimean-Congo hemorrhagic fever, a highly contagious viral disease endemic to more than 30 countries, has limited treatment options. Our results demonstrate that NP favors the translation of a reporter mRNA harboring the viral mRNA 5' UTR. It is highly likely that CCHFV uses an NP-mediated translation strategy for the rapid synthesis of viral proteins during the course of infection. Shutdown of this translation mechanism might selectively impact viral protein synthesis, suggesting that an NP-mediated translation strategy is a target for therapeutic intervention against this viral disease.

CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation.[Pubmed:25883264]

Proc Natl Acad Sci U S A. 2015 May 12;112(19):5875-82.

Mitosis is commonly thought to be associated with reduced cap-dependent protein translation. Here we show an alternative control mechanism for maintaining cap-dependent translation during mitosis revealed by a viral oncoprotein, Merkel cell polyomavirus small T (MCV sT). We find MCV sT to be a promiscuous E3 ligase inhibitor targeting the anaphase-promoting complex, which increases cell mitogenesis. MCV sT binds through its Large T stabilization domain region to cell division cycle protein 20 (Cdc20) and, possibly, cdc20 homolog 1 (Cdh1) E3 ligase adapters. This activates cyclin-dependent kinase 1/cyclin B1 (CDK1/CYCB1) to directly hyperphosphorylate eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP1) at authentic sites, generating a mitosis-specific, mechanistic target of rapamycin (mTOR) inhibitor-resistant delta phospho-isoform not present in G1-arrested cells. Recombinant 4E-BP1 inhibits capped mRNA reticulocyte translation, which is partially reversed by CDK1/CYCB1 phosphorylation of 4E-BP1. eIF4G binding to the eIF4E-m(7)GTP cap complex is resistant to mTOR inhibition during mitosis but sensitive during interphase. Flow cytometry, with and without sT, reveals an orthogonal pH3(S10+) mitotic cell population having higher inactive p4E-BP1(T37/T46+) saturation levels than pH3(S10-) interphase cells. Using a Click-iT flow cytometric assay to directly measure mitotic protein synthesis, we find that most new protein synthesis during mitosis is cap-dependent, a result confirmed using the eIF4E/4G inhibitor drug 4E1RCat. For most cell lines tested, cap-dependent translation levels were generally similar between mitotic and interphase cells, and the majority of new mitotic protein synthesis was cap-dependent. These findings suggest that mitotic cap-dependent translation is generally sustained during mitosis by CDK1 phosphorylation of 4E-BP1 even under conditions of reduced mTOR signaling.

Regulation of cardiac expression of the diabetic marker microRNA miR-29.[Pubmed:25062042]

PLoS One. 2014 Jul 25;9(7):e103284.

Diabetes mellitus (DM) is an independent risk factor for heart disease and its underlying mechanisms are unclear. Increased expression of diabetic marker miR-29 family miRNAs (miR-29a, b and c) that suppress the pro-survival protein Myeloid Cell Leukemia 1(MCL-1) is reported in pancreatic beta-cells in Type 1 DM. Whether an up-regulation of miR-29 family miRNAs and suppression of MCL-1 (dysregulation of miR-29-MCL-1 axis) occurs in diabetic heart is not known. This study tested the hypothesis that insulin regulates cardiac miR-29-MCL-1 axis and its dysregulation correlates with DM progression. In vitro studies with mouse cardiomyocyte HL-1 cells showed that insulin suppressed the expression of miR-29a, b and c and increased MCL-1 mRNA. Conversely, Rapamycin (Rap), a drug implicated in the new onset DM, increased the expression of miR-29a, b and c and suppressed MCL-1 and this effect was reversed by transfection with miR-29 inhibitors. Rap inhibited mammalian target of rapamycin complex 1 (mTORC1) signaling in HL-1 cells. Moreover, inhibition of either mTORC1 substrate S6K1 by PF-4708671, or eIF4E-induced translation by 4E1RCat suppressed MCL-1. We used Zucker diabetic fatty (ZDF) rat, a rodent model for DM, to test whether dysregulation of cardiac miR-29-MCL-1 axis correlates with DM progression. 11-week old ZDF rats exhibited significantly increased body weight, plasma glucose, insulin, cholesterol, triglycerides, body fat, heart weight, and decreased lean muscle mass compared to age-matched lean rats. Rap treatment (1.2 mg/kg/day, from 9-weeks to 15-weeks) significantly reduced plasma insulin, body weight and heart weight, and severely dysregulated cardiac miR-29-MCL1 axis in ZDF rats. Importantly, dysregulation of cardiac miR-29-MCL-1 axis in ZDF rat heart correlated with cardiac structural damage (disorganization or loss of myofibril bundles). We conclude that insulin and mTORC1 regulate cardiac miR-29-MCL-1 axis and its dysregulation caused by reduced insulin and mTORC1 inhibition increases the vulnerability of a diabetic heart to structural damage.

Description

4E1RCat is an inhibitor of cap-dependent translation, and inhibits eIF4E:eIF4GI interaction, with an IC50 an of ∼4 μM.

Keywords:

4E1RCat,328998-25-0,Natural Products,Others, buy 4E1RCat , 4E1RCat supplier , purchase 4E1RCat , 4E1RCat cost , 4E1RCat manufacturer , order 4E1RCat , high purity 4E1RCat

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: